Medicine guide
Inluriyo 200 mg
As listed in the register: Inluriyo 200 mg, comprimés pelliculés
200 mg ·
- Prescription only
- Cancer treatments and immune-system medicines
- Active substance
- Imlunestrantum
- Made by
- Eli Lilly (Suisse) SA
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Estrogenrezeptor (ER)-positiver, humaner epidermaler Wachstumsfaktor-Rezeptor-2 (HER2)-negativer, Estrogenrezeptor-1 (ESR1)-mutierter, fortgeschrittener oder metastasierter Brustkrebs
From the official label · 2026-09-30 · Swissmedic
Details
| Made by | Eli Lilly (Suisse) SA |
|---|---|
| Active substance | Imlunestrantum |
| Used in | Cancer treatments and immune-system medicines |
| Strength | 200 mg |
| Classification | L02BA · Cancer treatments and immune-system medicines |
| Dispensing (as stated by the register) | Abgabekategorie B |
| Name in the register | Inluriyo 200 mg, comprimés pelliculés |
| Packs | 28 Tablette(n) · 56 Tablette(n) |
| Zulassungsnummer | 70233 |
| Dosisstärke | 1 |
Source: Zugelassene Packungen Humanarzneimittel · 2026-09-30 · not reviewed by a clinician
Quelle: Swissmedic. The publisher’s terms do not grant reproduction, so text is shortened and linked. Publisher’s terms.